Морфологічні особливості ураження внутрішньопечінкових жовчних шляхів у дітей з аутоімунними захворюваннями печінки

M. B. Dyba; T. D. Zadorozhna; V. S. Berezenko

doi:10.14739/2310-1237.2025.2.334459

Authors

M. B. Dyba SI “Ukrainian Center of Maternity and Childhood of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0002-9463-7867
T. D. Zadorozhna SI “Ukrainian Center of Maternity and Childhood of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0003-2787-603X
V. S. Berezenko Bogomolets National Medical University, Kyiv, Ukraine https://orcid.org/0000-0002-3777-5251

DOI:

https://doi.org/10.14739/2310-1237.2025.2.334459

Keywords:

liver diseases, autoimmune diseases, children, liver biopsy, biliary phenotype, ductules

Abstract

Involvement of small intrahepatic bile ducts is a characteristic but underexplored feature of autoimmune liver diseases (AILD) in children. A distinctive aspect of pediatric AILD is the overlap between autoimmune hepatitis (AIH) and primary sclerosing cholangitis (PSC), which complicates differential diagnosis – especially in cases with isolated small-duct injury and absence of typical PSC features on MRCP.

The aim of the study was to assess the spectrum and frequency of biliary injury in children with autoimmune hepatitis, autoimmune sclerosing cholangitis, and primary sclerosing cholangitis using the modified Nakanuma scoring system and additional morphological criteria of cholestasis.

Materials and methods. Sixty-nine children with AILD were included: 26 with AIH, 29 with ASC, and 14 with PSC. Liver biopsies were evaluated using the Nakanuma classification. Additional features assessed included periductal fibrosis and signs of cholestasis (biliary interface, rosettes, ballooning / feathery hepatocyte degeneration, portal / periportal edema, and mucobilia).

Results. The median age at diagnosis was 11 years (IQR: 8–14). Advanced liver fibrosis (F3–F4) was present in 54 % of AIH, 79 % of ASC, and 43 % of PSC cases. Cirrhosis was observed in 24 % of ASC, 19 % of AIH, and 7 % of PSC patients. Inflammatory bowel disease was common in biliary phenotypes – detected in 72 % of ASC and 71 % of PSC patients, and in only 3.8 % of AIH cases. According to MRCP, large-duct involvement was seen in 71 % of PSC and 72 % of ASC patients, while isolated small-duct injury was found in 29 % and 28 %, respectively. ASC and PSC patients showed a broader range of biliary lesions compared to AIH. Statistically significant differences were observed in the frequency of ductopenia ≥ grade 2 (ASC – 52 %, PSC – 64 %, AIH – 19 %), advanced periductal fibrosis ≥ grade 3 (ASC – 62 %, PSC – 71 %, AIH – 8 %), and mucobilia (ASC – 66 %, PSC – 36 %, AIH – 4 %; p < 0.001). Cumulative scoring of biliary features reliably distinguished AIH (mean 3.4 ± 1.4) from ASC (6.4 ± 1.6) and PSC (6.7 ± 1.9, p < 0.001).

Conclusions. Extended morphological analysis using the Nakanuma classification and additional biliary injury criteria improves diagnostic accuracy for identifying the biliary phenotype of AILD in children, including small-duct variants of ASC and PSC. This approach supports more precise diagnosis and individualized treatment strategies.

Author Biographies

M. B. Dyba, SI “Ukrainian Center of Maternity and Childhood of the National Academy of Medical Sciences of Ukraine”, Kyiv

MD, PhD, Senior Researcher, Department of Pediatric Hepatology and Comorbidities in Children

T. D. Zadorozhna, SI “Ukrainian Center of Maternity and Childhood of the National Academy of Medical Sciences of Ukraine”, Kyiv

MD, PhD, DSc, Professor, Head of the Laboratory of Pathomorphology; Corresponding Member of the National Academy of Medical Sciences of Ukraine

V. S. Berezenko, Bogomolets National Medical University, Kyiv

MD, PhD, DSc, Professor, Head of Department of Pediatrics; Head of Department of Pediatric Hepatology and Comorbidities in Children, Ukrainian Center of Maternity and Childhood of the National Academy Sciences of Ukraine, Kyiv

References

Mieli-Vergani G, Vergani D, Baumann U, Czubkowski P, Debray D, Dezsofi A, et al. Diagnosis and Management of Pediatric Autoimmune Liver Disease: ESPGHAN Hepatology Committee Position Statement. J Pediatr Gastroenterol Nutr. 2018;66(2):345-60. doi: https://doi.org/10.1097/MPG.0000000000001801

Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology. 2001;33(3):544-53. doi: https://doi.org/10.1053/jhep.2001.22131

Ramonet M, Ramirez-Rodriguez N, Álvarez Chávez F, Arregui MC, Boldrini G, Botero Osorio V, et al. Autoimmune hepatitis in pediatrics, a review by the Working Group of the Latin American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Arch Argent Pediatr. 2022;120(4):281-7. English, Spanish. doi: https://doi.org/10.5546/aap.2022.eng.281

Anderson CM, Welle CL, Ludwig DR, Anderson MA, Khot R, Itani M, et al. Autoimmune Disorders of the Liver and Biliary Tract. Radiographics. 2025;45(4):e240126. doi: https://doi.org/10.1148/rg.240126. Erratum in: Radiographics. 2025;45(4):e259005. doi: https://doi.org/10.1148/rg.259005

European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of autoimmune hepatitis. J Hepatol. 2025;83(2):453-501. doi: https://doi.org/10.1016/j.jhep.2025.03.017

Kemme S, Mack CL. Pediatric Autoimmune Liver Diseases: Autoimmune Hepatitis and Primary Sclerosing Cholangitis. Pediatr Clin North Am. 2021;68(6):1293-307. doi: https://doi.org/10.1016/j.pcl.2021.07.006

Ricciuto A, Kamath BM, Hirschfield GM, Trivedi PJ. Primary sclerosing cholangitis and overlap features of autoimmune hepatitis: A coming of age or an age-ist problem? J Hepatol. 2023;79(2):567-75. doi: https://doi.org/10.1016/j.jhep.2023.02.030

Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020;72(2):671-722. doi: https://doi.org/10.1002/hep.31065

Nastasio S, Mosca A, Alterio T, Sciveres M, Maggiore G. Juvenile Autoimmune Hepatitis: Recent Advances in Diagnosis, Management and Long-Term Outcome. Diagnostics (Basel). 2023;13(17):2753. doi: https://doi.org/10.3390/diagnostics13172753

Nguyen CM, Kline KT, Stevenson HL, Khan K, Parupudi S. Small duct primary sclerosing cholangitis: A discrete variant or a bridge to large duct disease, a practical review. World J Hepatol. 2022;14(3):495-503. doi: https://doi.org/10.4254/wjh.v14.i3.495

Kozaka K, Sheedy SP, Eaton JE, Venkatesh SK, Heiken JP. Magnetic resonance imaging features of small-duct primary sclerosing cholangitis. Abdom Radiol (NY). 2020;45(8):2388-99. doi: https://doi.org/10.1007/s00261-020-02572-w

Ringe KI, Bergquist A, Lenzen H, Kartalis N, Manns MP, Wacker F, et al. Clinical features and MRI progression of small duct primary sclerosing cholangitis (PSC). Eur J Radiol. 2020;129:109101. doi: https://doi.org/10.1016/j.ejrad.2020.109101

Bowlus CL, Arrivé L, Bergquist A, Deneau M, Forman L, Ilyas SI, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023;77(2):659-702. doi: https://doi.org/10.1002/hep.32771

Balitzer D, Shafizadeh N, Peters MG, Ferrell LD, Alshak N, Kakar S. Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria. Mod Pathol. 2017;30(5):773-83. doi: https://doi.org/10.1038/modpathol.2016.267

Beer A, Dienes HP. Autoimmune hepatitis-is histology conclusive? Ann Transl Med. 2021;9(8):733. doi: https://doi.org/10.21037/atm-20-5084

Sakulsaengprapha V, Wasuwanich P, Naraparaju G, Korotkaya Y, Thawillarp S, Oshima K, et al. Applicability of International Autoimmune Hepatitis Group (IAIHG) Scoring System for Autoimmune Hepatitis in Pediatrics. Biology (Basel). 2023;12(3):479. doi: https://doi.org/10.3390/biology12030479. Erratum in: Biology (Basel). 2023;12(5):727. doi: https://doi.org/10.3390/biology12050727

Stevens JP, Gupta NA. Recent Insights into Pediatric Primary Sclerosing Cholangitis. Clin Liver Dis. 2022 Aug;26(3):489-519. doi: https://doi.org/https://doi.org/10.1016/j.cld.2022.03.009

Di Giorgio A, D'Adda A, Marseglia A, Sonzogni A, Licini L, Nicastro E, et al. Biliary features in liver histology of children with autoimmune liver disease. Hepatol Int. 2019;13(4):510-8. doi: https://doi.org/10.1007/s12072-019-09948-1

Warner S, Rajanayagam J, Russell E, Lloyd C, Ferguson J, Kelly DA, et al. Biliary disease progression in childhood onset autoimmune liver disease: A 30-year follow-up into adulthood. JHEP Rep. 2023;6(2):100901. doi: https://doi.org/10.1016/j.jhepr.2023.100901

European Association for the Study of the Liver. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol. 2022;77(3):761-806. doi: https://doi.org/10.1016/j.jhep.2022.05.011. Erratum in: J Hepatol. 2023;79(5):1339. doi: https://doi.org/10.1016/j.jhep.2023.09.005

Cazzagon N, Sarcognato S, Catanzaro E, Bonaiuto E, Peviani M, Pezzato F, et al. Primary Sclerosing Cholangitis: Diagnostic Criteria. Tomography. 2024;10(1):47-65. doi: https://doi.org/10.3390/tomography10010005

Czaja AJ, Muratori P, Muratori L, Carpenter HA, Bianchi FB. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver Int. 2004;24(4):322-9. doi: https://doi.org/10.1111/j.1478-3231.2004.0924.x

Di Giorgio A, Vergani D, Mieli-Vergani G. Cutting edge issues in juvenile sclerosing cholangitis. Dig Liver Dis. 2022;54(4):417-27. doi: https://doi.org/10.1016/j.dld.2021.06.028

Nakanuma Y, Zen Y, Harada K, Sasaki M, Nonomura A, Uehara T, et al. Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement. Pathol Int. 2010;60(3):167-74. doi: https://doi.org/10.1111/j.1440-1827.2009.02500.x

Harada K, Hsu M, Ikeda H, Zeniya M, Nakanuma Y. Application and validation of a new histologic staging and grading system for primary biliary cirrhosis. J Clin Gastroenterol. 2013;47(2):174-81. doi: https://doi.org/10.1097/MCG.0b013e31827234e4

de Vries EM, Verheij J, Hubscher SG, Leeflang MM, Boonstra K, Beuers U, et al. Applicability and prognostic value of histologic scoring systems in primary sclerosing cholangitis. J Hepatol. 2015;63(5):1212-9. doi: https://doi.org/10.1016/j.jhep.2015.06.008

Yamashiki N, Haga H, Ueda Y, Ito T, Yagi S, Kamo N, et al. Use of Nakanuma staging and cytokeratin 7 staining for diagnosing recurrent primary biliary cholangitis after living-donor liver transplantation. Hepatol Res. 2020;50(4):478-87. doi: https://doi.org/10.1111/hepr.13476

Bateman AC, Hübscher SG. Cytokeratin expression as an aid to diagnosis in medical liver biopsies. Histopathology. 2010;56(4):415-25. doi: https://doi.org/10.1111/j.1365-2559.2009.03391.x

Sakellariou S, Michaelides C, Voulgaris T, Vlachogiannakos J, Manesis E, Tiniakos DG, et al. Keratin 7 expression in hepatic cholestatic diseases. Virchows Arch. 2021;479(4):815-24. doi: https://doi.org/10.1007/s00428-021-03152-z. Erratum in: Virchows Arch. 2021;479(4):825-6. doi: https://doi.org/10.1007/s00428-021-03181-8

Nakanuma Y, Tsuneyama K, Harada K. Pathology and pathogenesis of intrahepatic bile duct loss. J Hepatobiliary Pancreat Surg. 2001;8(4):303-15. doi: https://doi.org/10.1007/s005340170002

Nagore N, Howe S, Boxer L, Scheuer PJ. Liver cell rosettes: structural differences in cholestasis and hepatitis. Liver. 1989;9(1):43-51. doi: https://doi.org/10.1111/j.1600-0676.1989.tb00377.x

Burt AD, Ferrell LD, Hübscher SG. MacSween’s pathology of the liver. 8th ed. London, England: Elsevier Health Sciences; 2023.

Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology. 2001;34(4 Pt 1):659-65. doi: https://doi.org/10.1053/jhep.2001.27562

Khot R, Shelman NR, Ludwig DR, Nair RT, Anderson MA, Venkatesh SK, et al. Acquired ductopenia: an insight into imaging findings. Abdom Radiol (NY). 2025;50(1):152-68. doi: https://doi.org/10.1007/s00261-024-04462-x

Bessone F, Hernández N, Tanno M, Roma MG. Drug-Induced Vanishing Bile Duct Syndrome: From Pathogenesis to Diagnosis and Therapeutics. Semin Liver Dis. 2021;41(3):331-48. doi: https://doi.org/10.1055/s-0041-1729972. Erratum in: Semin Liver Dis. 2021;41(3):e1. doi: https://doi.org/10.1055/s-0041-1732497

Hercun J, Noureddin M, Noureddin N, Eccleston J, Woolridge D, Liang TJ, et al. Longitudinal Assessment of Bile Duct Loss in Primary Biliary Cholangitis. Am J Gastroenterol. 2022;117(12):2075-8. doi: https://doi.org/10.14309/ajg.0000000000001985

Nakanuma Y, Tsuneyama K, Sasaki M, Harada K. Destruction of bile ducts in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol. 2000;14(4):549-70. doi: https://doi.org/10.1053/bega.2000.0103

Wasuwanich P, Choudry H, So JM, Lowry S, Karnsakul W. Vanishing bile duct syndrome after drug-induced liver injury. Clin Res Hepatol Gastroenterol. 2022;46(9):102015. doi: https://doi.org/10.1016/j.clinre.2022.102015

Wang NL, Chen L, Lin J, Lu Y, Fang WY, Xie XB, et al. Non-invasive biomarkers for identification of vanishing bile duct syndrome among children with acute cholestatic hepatitis. Transl Pediatr. 2023;12(10):1782-90. doi: https://doi.org/10.21037/tp-23-305

Sabu S, Chakrabarty G, Shahid F. Vanishing Bile Duct Syndrome: A Differential Diagnosis for Painless Jaundice. Cureus. 2024;16(9):e68724. doi: https://doi.org/10.7759/cureus.68724

Russe-Russe JR, Liu L, Thuluvath PJ. COVID-related Vanishing Bile Duct Syndrome (VBDS). J Clin Exp Hepatol. 2024;14(2):101302. doi: https://doi.org/10.1016/j.jceh.2023.11.002

Sato K, Marzioni M, Meng F, Francis H, Glaser S, Alpini G. Ductular Reaction in Liver Diseases: Pathological Mechanisms and Translational Significances. Hepatology. 2019;69(1):420-30. doi: https://doi.org/10.1002/hep.30150. Erratum in: Hepatology. 2019;70(3):1089. doi: https://doi.org/10.1002/hep.30878

Ariño S, Aguilar-Bravo B, Coll M, Lee WY, Peiseler M, Cantallops-Vilà P, et al. Ductular reaction-associated neutrophils promote biliary epithelium proliferation in chronic liver disease. J Hepatol. 2023;79(4):1025-36. doi: https://doi.org/10.1016/j.jhep.2023.05.045

Sorrentino G. Microenvironmental control of the ductular reaction: balancing repair and disease progression. Cell Death Dis. 2025;16(1):246. doi: https://doi.org/10.1038/s41419-025-07590-4

Mavila N, Siraganahalli Eshwaraiah M, Kennedy J. Ductular Reactions in Liver Injury, Regeneration, and Disease Progression-An Overview. Cells. 2024;13(7):579. doi: https://doi.org/10.3390/cells13070579

Sticova E, Fabian O. Morphological aspects of small-duct cholangiopathies: A minireview. World J Hepatol. 2023;15(4):538-53. doi: https://doi.org/10.4254/wjh.v15.i4.538

Lawson KL, Wang HL. Primary Sclerosing Cholangitis, Small Duct Primary Sclerosing Cholangitis, IgG4-Related Sclerosing Cholangitis, and Ischemic Cholangiopathy: Diagnostic Challenges on Biopsy. Surg Pathol Clin. 2023;16(3):533-48. doi: https://doi.org/10.1016/j.path.2023.04.008

Pollheimer MJ, Fickert P, Stieger B. Chronic cholestatic liver diseases: clues from histopathology for pathogenesis. Mol Aspects Med. 2014;37:35-56. doi: https://doi.org/10.1016/j.mam.2013.10.001